JE
BCLI

JMAC Enterprises’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

JMAC Enterprises’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,362
Closed -$15.1K – 170
2024
Q3 		$15.1K Hold
4,362
– – ﹤0.01% 180
2024
Q2 		$22.1K Hold
4,362
– – ﹤0.01% 173
2024
Q1 		$36.9K Hold
4,362
– – 0.01% 167
2023
Q4 		$17.9K Hold
4,362
– – ﹤0.01% 169
2023
Q3 		$13.1K Buy
4,362
+1,667
+62% +$37.9K ﹤0.01% 160
2023
Q2 		$83.3K Hold
2,695
– – 0.02% 170
2023
Q1 		$133K Hold
2,695
– – 0.03% 174
2022
Q4 		$66.3K Hold
2,695
– – 0.02% 173
2022
Q3 		$179K Sell
2,695
-334
-11% -$16.8K 0.05% 169
2022
Q2 		$125K Hold
3,029
– – 0.03% 175
2022
Q1 		$153K Hold
3,029
– – 0.04% 175
2021
Q4 		$144K Buy
+3,029
New +$149K 0.03% 171

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $26B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $699M AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return